Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1

AIDS

Volumn 24, Issue 4, 2010, Pages 609-611

  Choi, Byeong Sun ^a   Lee, Hak Sung ^a   Oh, You Take ^a   Hyun, Young Lan ^b   Ro, Sunggu ^b   Kim, Sung Soon ^a   Hong, Kee Jong ^a  

^a Korea National Institute of Health   (South Korea)

^b Crystal Genomics   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BELINOSTAT; CG 05; CG 06; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VORINOSTAT;

ACETYLATION; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT PERIOD; PRIORITY JOURNAL; PROVIRUS; T LYMPHOCYTE; VIRUS REACTIVATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HUMANS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 77649245440     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333bfa1     Document Type: Article

References (20)

1. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, Fauci AS. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med 2000; 6:757-761.
2. Williams SA, Greene WC. Host factors regulating postintegra-tion latency of HIV. Trends Microbiol 2005; 13:137-139.
3. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine 2007; 39:63-74.
4. KimH,Perelson AS. Viral and latent reservoir persistenceinHIV-1-infected patients on therapy. PLoS Comput Biol 2006; 2:e135.
5. Sedaghat AR, Siliciano RF, Wilke CO. Low-level HIV-1 replication and the dynamics of the resting CD4R T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 2008; 8:2.
6. Lieberman PM. Chromatin regulation of virus infection. Trends Microbiol 2006; 14:132-140.
7. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, Jeang KT. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 tat. J Biol Chem 1998; 273:24898-24905.
8. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, et al. HIV-1 tat transcriptional activity is regulated by acetyla-tion. Embo J 1999; 18:6106-6118.
9. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. Acetylation of the HIV-1 tat protein by p300 is important for its transcriptional activity. Curr Biol 1999; 9:1489-1492.
10. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyl-transferases regulate HIV-1 enhancer activity in vitro. Genes Dev 1997; 11:3327-3340.
11. Steger DJ, Eberharter A, John S, Grant PA, Workman JL. Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. Proc Natl Acad Sci USA 1998; 95:12924-12929.
12. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. Embo J 2006; 25:139-149.
13. Demonte D, Quivy V, Colette Y, Van Lint C. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol 2004; 68:1231-1238.
14. Varier RA, Kundu TK. Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy. Curr Pharm Des 2006; 12:1975-1993.
15. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
16. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wie-gand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555.
17. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836.
18. Vandergeeten C, Quivy V, Moutschen M, Van Lint C, Piette J, Legrand-Poels S. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha R TSA. Biochem Pharmacol 2007; 73:1738-1748.
19. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone dea-cetylase inhibitor PXD101. Mol Cancer Ther 2003; 2:721-728.
20. Shahbazian MD, Grunstein M. Functions of site-specific his-tone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75-100.